RPHM 18.2 (+5.2%)
US75974E1038BiotechnologyBiotechnology

Reneo Pharmaceuticals (RPHM) Stock Highlights

18.2 | +5.2%
2024-12-21 07:09:51
Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.

Statistics

Range Today
16.8 19
Volume Today 42.36K
Range 1 Year
0.98 17.5
Volume 1 Year 101.24M
Range 3 Year
0.98 17.5
Volume 3 Year 140.39M
Range 10 Year
0.98 17.5
Volume 10 Year 152.49M

Highlights

Market Capitalization 60.84M (small)
Floating Shares 3.33M
Current Price 18.2
Price To Earnings -0.1
Price To Book 0.79
Earnings Per Share -16.8
Payout Ratio 0%

Performance

Latest +5.2%
1 Month +27.27%
3 Months +1129.73%
6 Months +958.14%
1 Year +159.26%
3 Years +160%
5 Years +21.33%
10 Years +21.33%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.